Kenneth Chien
Co-Founder @ Moderna
Kenneth Chien is a Series B investor at Moderna focused on Biotechnology and Health Care. Kenneth Chien is the Co-Founder of Moderna Therapeutics.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Kenneth Chien invests in
Stages Kenneth Chien invests in
Countries Kenneth Chien invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (100%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
- Medical Device 1 (50%)
Stage
- Series B 1 (50%)
- Funding Round 1 (50%)
Country
- Sweden 1 (50%)
- Belgium 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
etherna immunotherapies
|
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable andsafer enhancement of the patient’s immune system than any other similar approach investigated until now. | $38.9M / Series B / Aug 23, 2022 | |
SmartCella
|
SmartCella is an innovative biotechnology and medtech company. Sweden. SmartCella’s therapeutic mission is to develop treatments for patients running out of options. The company has three main business units, Procella Therapeutics, Smartwise and SvedMed Solutions. | $37.7M / Sep 27, 2021 |
Co-Investors
About Moderna
Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
Moderna Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eric Ma
Principal Data Scientist
|
|||
|
Kenneth Chien
Co-Founder
|
|||
Marcello Damiani
Chief Digital & Operational Excellence Officer
|
|||
John Mendlein
President, Corporate and Product Strategy
|
|||
Noubar Afeyan
Chairman & Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kenneth Chien invest in?
Kenneth Chien invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kenneth Chien?
Public channels for Kenneth Chien include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kenneth Chien last invest?
The most recent investment recorded for Kenneth Chien closed in Aug 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
